YLYu Liu

Yu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Qi Li

    Department of General Surgery, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, People’s Republic of China

    3 shared publications
  • Kang Yu

    Department of Clinical Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Chun-Wei Li

    Department of Clinical Nutrition, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China

    1 shared publication
  • Chun-Wei Li

    Department of Clinical Nutrition, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    1 shared publication
  • Chunli Guo

    1 shared publication
  • Fu-Quan Zhang

    Department of General Surgery, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Prognostic Significance of the CRP-Albumin-Lymphocyte Index (CALLY) in Triple Negative Breast Cancer Patients: A Real-World Retrospective Study

    by Yu Liu, Fuquan Zhang, Chunli Guo, Qi Li

    Objective: This study aims to explore the prognostic utility of the CRP-Albumin- Lymphocyte Index (CALLY) in triple-negative breast cancer (TNBC) patients undergoing curative resection. Methods: A retrospective analysis of 172 TNBC patients treated surgically between January 2011 and December 2020 was conducted. Preoperative CALLY was calculated as (albumin × lymphocyte) / CRP Survival curves for disease free survival (DFS) and overall survival (OS) were estimated using Kaplan-Meier method, and differences between groups were statistically evaluated by Log rank test. Univariate and multivariate Cox proportional hazards regression model were constructed incorporating variables identified as potential independent variables. Nomograms were established according to the multivariate analysis results, and with internal validation performed using the consistency index (C-index), calibration curve, and decision curve analyses (DCA). Results: Patients were stratified into low CALLY group (< 0.44, n=83) and high CALLY group (≥ 0.44, n=89) based on the optimal cutoff value of CALLY determined by receiver operating characteristic curve (ROC) analysis. High CALLY correlated with significantly prolonged DFS (32.54 vs. 28.97 months; χ2=14.070, P=0.0002) and OS (59.87 vs. 45.20 months; χ2=17.800, P< 0.0001). Multivariate regression analysis revealed that CALLY as an independent predictor of DFS (hazard ratio [HR]: 0.275, 95% confidence interval [CI]: 0.140– 0.539, P< 0.001) and OS (HR: 0.372, 95% CI: 0.182– 0.764, P = 0.007). Nomograms integrating CALLY, TOP2A, and postoperative chemotherapy demonstrated robust predictive accuracy for DFS (C-index: 0.717, 95% CI 0.595– 0.814) and OS (C-index: 0.725, 95% CI 0.605– 0.819). Conclusion: CALLY reflects systemic inflammation, nutrition, and immune status, and represents a novel prognostic index for TNBC. Its integration into nomograms enhances personalized risk stratification and treatment decision-making.


  • Open Access

    Visceral and Subcutaneous Fat Deposits Exhibit Distinct Roles in the Initiation and Progression of Breast Cancer

    by Yu Zhang, Qi Li, Li Zhao, Yi Pang, Lin Li, Wei-Wei Niu, Yu Xing, Yu Liu, Fu-Quan Zhang, Yu-Chen Fan, et al.

    Purpose: Evidence suggests that ectopic fat deposition and muscle atrophy may contribute to tumor development and progression; however, their dual roles in breast cancer (BC) remain incompletely understood. This study aims to elucidate the complex relationships between specific body composition features and both BC initiation and progression. Patients and methods: A multicenter observational study was conducted from March 2020 to May 2025, integrating case-control and longitudinal data on body composition parameters, covariates, and survival outcomes from 213 BC patients and 430 cancer-free controls. The case-control analysis employed inverse probability weighting, lasso and logistic regression to evaluate associations between body composition and BC risk. The XGBoost model was used to further identify key body composition predictors. Kaplan-Meier and Cox regression analyses were conducted to evaluate the effect of body composition parameters on distant metastasis-free survival (DMFS) in BC patients following radical mastectomy. Results: Trunk muscle mass (TMM) exerted a protective effect against BC development (OR=0.965, 95% CI: 0.949~0.982), whereas muscle mass (MM: OR=1.027, 95% CI: 1.008~1.047) trunk fat mass (TFM: OR=1.046, 95% CI: 1.025~1.068) and visceral adipose tissue (VAT: OR=1.003, 95%: 1.0005~1.005) emerged as independent risk factors, even after adjusting for menopause status, comorbidities, laboratory indices, and lifestyle factors. The XGBoost model corroborated TFM, VAT, and TMM as pivotal predictors of carcinogenesis. Paradoxically, in post-mastectomy BC patients, higher subcutaneous adipose tissue compartments, specifically TFM (HR= 0.794, 95% CI: 0.634~0.994) was significantly correlated with improved DMFS, particularly among postmenopausal women (HR=0.721, 95% CI: 0.530~0.981), while VAT showed no significant impact on survival. Higher LMM was also associated with improved DMFS in postmenopausal women. Conclusion: This study reveals a paradoxical role of adipose tissue in breast cancer, as it may promote tumorigenesis yet confer a post-mastectomy survival advantage. Body composition’s prognostic complexity necessitates targeted therapies targeting fat-muscle crosstalk in cancer management.


  • Open Access

    Sarcopenic obesity exacerbates gastric cancer prognosis via increased intermuscular and visceral fat accumulation

    by Chun-Wei Li, Qi Li, Yu Liu, Yu Zhang, Zhong-Kui Wang, Yu Xing, Yi-Shan Niu, Yi Pang, Kang Yu

    Ectopic fat distribution reflects patient’s metabolic profile, shaping the tumor microenvironment, which may be a key prognostic indicator. Our study pursues to explore the independent and combined effects of muscle atrophy and abnormal fat distribution on survival in gastric cancer patients. This retrospective cohort study analyzed body composition in 283 gastric cancer patients from Center Hospital, Tianjin University (June 2016–May 2025) using pretreatment CT at L3, assessing muscle mass, intermuscular, and visceral fat. Ectopic fat phenotypes included visceral obesity (increased visceral adipose tissue, VAT) and myosteatosis (reduced skeletal muscle density, SMD). Associations between body composition parameters/phenotypes and progression-free survival (PFS), overall survival (OS), and cachexia-related survival (CRS) were evaluated using Kaplan–Meier analysis with log-rank tests and Cox proportional hazards regression. Of the 283 patients, 32 patients (11.3%) were BMI-define obese, 139 patients (49.1%) showed visceral obesity, and 176 patients (62.2%) presented with myosteatosis. Sarcopenia was present in 234 patients (82.7%), and 151 patients (53.4%) presented with a combination of sarcopenia and myosteatosis. During a median follow-up of 41 months (2–108 months), 53 patients developed metastasis, 6 relapse, and 142 died. Skeletal muscle mass (Normal Attenuation Muscle Area, NAMA, HR = 0.989, 95% CI 0.980–0.998, P = 0.022, for PFS) and quality (SMD, HR = 0.975, 95% CI 0.955–0.995, P = 0.013, for PFS) serve as protective prognostic factors after multiple covariate adjustments. Multivariate analyses identified all adiposity-related parameters, including Low Attenuation Muscle Area (LAMA, HR = 1.015, 95% CI 1.003–1.026, P = 0.012, for PFS), intermuscular adipose tissue (IMAT, HR = 1.018, 95% CI 1.002–1.034, P = 0.027, for PFS), and VFI (HR = 1.008, 95% CI 1.001–1.015, P = 0.042) as negative indicators for survival. Sensitivity analyses confirmed these associations. Besides, IMAT, LAMA, and VFI significantly influence prognosis in advanced patients (TNM stage III–IV). Kaplan–Meier survival analysis revealed sarcopenic visceral obesity markedly reduces survival; when combined with myosteatosis (SMVO), this combined phenotype further exacerbated CRS (5-year CRS: 74.7% in SMVO, P = 0.019) beyond the effects of individual phenotypes. Sarcopenic obesity (myosteatosis/visceral obesity) can identify poorer prognosis in gastric cancer patients, especially male patients. It is crucial for obese gastric cancer patients to evaluate their body composition, specifically focusing on fat distribution. Trial registration: Registered in August 2016, NCT02873676 at www.clinicaltrials.gov .